Urinary cyclophilin A as an early marker of chronic kidney disease with underlying type 2 diabetes


Here are the Urinary cyclophilin A as an early marker of chronic kidney disease with underlying type 2 diabetes journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Urinary cyclophilin a as an early marker of leaky, urinary anatomy, urinary cyclophilin a as an early marker of tissue, urinary cyclophilin a as an early marker of chronic kidney, urinary and fecal incontinence, urinary cyclophilin a as an early marker of significance, urinary analgesic, urinary cyclophilin a as an early marker of chronic kidney disease, urinary cyclophilin protein.

Urinary cyclophilin A as an early marker of chronic kidney disease with underlying type 2 diabetes

Cyclophilin A (CypA) is a novel renal inflammation biomarker, with levels altered in various diseases, particularly in patients with diabetes mellitus (DM) and kidney damage. This study aimed to investigate the correlation between urinary cyclophilin A (uCypA) and chronic kidney disease (CKD) conditions with and without type 2 diabetes mellitus (T2DM) using an in-house enzyme-linked immunoassay (ELISA) method. A uCypA strip-test prototype was also developed. An indirect ELISA was performed to determine the uCypA levels. A 0.48 µg/mL uCypA cutoff differentiated healthy patients from those with early-stage CKD (stages I and II). The uCypA levels were significantly increased in patients with progression of renal deterioration, especially in the T2DM with late-stage CKD group, compared to the control group. Fasting blood sugar (FBS), estimated glomerular filtration rate (eGFR), albumin/creatinine ratio, and metformin use were associated with uCypA levels. Multinomial logistic r egression analysis revealed an association between uCypA levels and T2DM diagnosed for over five years and early-stage CKD. This finding shows that uCypA could be used as a biomarker for distinguishing early-stage CKD as well as T2DM complications, which is beneficial for patients to be aware of their health status and change their behavior to slow kidney deterioration. © The Author(s) 2024.

Authors : Chatchawal P.; Tippayawat P.; Somdee T.; Ngernpimai S.; Wongwattanakul M.; Sae-ung N.; Anutrakulchai S.; Kraiklang R.

Source : Nature Research

Article Information

Year 2024
Type Article
DOI 10.1038/s41598-024-73994-5
ISSN 20452322
Volume 14

You can download the article here


If You have any problem, contact us here


Support Us:

Download Now Buy me a coffee Request Paper Here